Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBECCA) nested within a compassionate use program.[BMC Cancer. 2016;16:412. doi: 10.1186/s12885-016-2440-9.]

6Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Adenis, A., de la Fouchardiere, C., Paule, B., Burtin, P., Tougeron, D., Wallet, J., … Andre, T. (2016, July 25). Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: Results from a multicenter study (REBECCA) nested within a compassionate use program.[BMC Cancer. 2016;16:412. doi: 10.1186/s12885-016-2440-9.]. BMC Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12885-016-2559-8

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free